Vanda Pharmaceuticals (VNDA) Sinks as Red Flags Raised
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) is under heavy pressure early following a negative article by The Street's Adam Feuerstein. Shares are down 16%.
"Vanda Pharmaceuticals (VNDA) tells a pretty compelling story about the development of tasimelteon for the treatment of a rare sleep-pattern disorder that affects blind people. Dig into the company's clinical work on tasimelteon, however, and you'll find a disturbingly large number of irregularities and red flags which should ring alarm bells for any investor betting on the drug's approval."
Full Story
"Vanda Pharmaceuticals (VNDA) tells a pretty compelling story about the development of tasimelteon for the treatment of a rare sleep-pattern disorder that affects blind people. Dig into the company's clinical work on tasimelteon, however, and you'll find a disturbingly large number of irregularities and red flags which should ring alarm bells for any investor betting on the drug's approval."
Full Story
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
- Uber fined $966 Million in the Netherlands for automating driver suspensions - Reuters
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
Create E-mail Alert Related Categories
Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
